ID: ALA537229

Max Phase: Preclinical

Molecular Formula: C24H26ClN3O4

Molecular Weight: 419.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(COc2ccc(C(=O)N[C@@H]3CCC[C@@H]3C(=O)NO)cc2)c2ccccc2n1.Cl

Standard InChI:  InChI=1S/C24H25N3O4.ClH/c1-15-13-17(19-5-2-3-7-21(19)25-15)14-31-18-11-9-16(10-12-18)23(28)26-22-8-4-6-20(22)24(29)27-30;/h2-3,5,7,9-13,20,22,30H,4,6,8,14H2,1H3,(H,26,28)(H,27,29);1H/t20-,22+;/m0./s1

Standard InChI Key:  NUGCYIIZTZNQHT-IKGOIYPNSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 419.48

Molecular Weight (Monoisotopic): 419.1845

AlogP: 3.53

#Rotatable Bonds: 6

Polar Surface Area: 100.55

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.86

CX Basic pKa: 5.02

CX LogP: 2.83

CX LogD: 2.81

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.42

Np Likeness Score: -0.89

References

1. Duan JJ, Chen L, Lu Z, Xue CB, Liu RQ, Covington MB, Qian M, Wasserman ZR, Vaddi K, Christ DD, Trzaskos JM, Newton RC, Decicco CP..  (2008)  Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.,  18  (1): [PMID:18032037] [10.1016/j.bmcl.2007.10.093]

Source

Source(1):

• Scientific Literature